Physician profile
Cathy Luo
NPI 1417964859
$2,863.00
in general payments reported to CMS, 2019-2025
25 companies · $177 in 2025
The $177 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $892 · 2020: $435 · 2021: $475 · 2022: $426 · 2023: $199 · 2024: $259 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $634.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $420.97 | 2021-2025 | Relistor |
| Lilly USA, LLC | $350.23 | 2019-2023 | Emgality |
| Collegium Pharmaceutical, INC. | $348.81 | 2019-2023 | Xtampza |
| Pfizer INC. | $315.66 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $216.34 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $214.33 | 2019-2021 | |
| Abbvie INC. | $119.87 | 2021-2023 | |
| Abbott Laboratories | $118.50 | 2019 | |
| Daiichi Sankyo INC. | $111.44 | 2019 | |
| Curonix LLC | $97.95 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Grt US Holding, INC. | $89.72 | 2021 | |
| Upsher-Smith Laboratories LLC | $88.48 | 2020-2022 | |
| Eisai INC. | $58.06 | 2020-2022 | |
| Allergan, INC. | $50.57 | 2020 | |
| Shionogi INC | $43.63 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $38.27 | 2021 | |
| Valinor Pharma, LLC | $35.60 | 2025 | Movantik |
| Zyla Life Sciences, INC. | $29.33 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $28.89 | 2025 | |
| Scilex Pharmaceuticals INC. | $20.07 | 2021 | |
| Amgen INC. | $13.53 | 2019 | |
| Integra Lifesciences Corporation | $13.50 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Amneal Pharmaceuticals LLC | $13.35 | 2023 | Lyvispah |
| Currax Pharmaceuticals LLC | $13.00 | 2022 | |
| Supernus Pharmaceuticals, INC. | $12.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cathy Luo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.